live In the news:
Ozempic maker Novo Nordisk wants the FDA to crack down on knockoff weight loss drugs - Novo Nordisk's weight loss drug Wegovy available in France from Tuesday - Denmark's Novo Nordisk plans to fly medicine to US amid port strike - US Congress calls on Denmark's Novo Nordisk to lower drug prices - Watch live: Senate HELP committee grills Novo Nordisk on weight loss drug pricing - Novo Nordisk is bigger than Denmark's economy -- but the prime minister isn't worried about another Nokia - Novo Nordisk faces US Senate grilling over price of weight loss drugs

Novo Nordisk

1 day ago
bookmarkSave

Key facts

In classification: organization

Summary

The company Novo Nordisk was founded in 1923 in the city of Bagsvaerd, Denmark. The company is part of the Health Care sector, specifically in the Biotechnology industry.

Business

Novo Nordisk is one of the companies in Denmark, one of the companies in Biotechnology and one of the companies in Health Care. Novo Nordisk is one of the 3,466,499 companies in our database.
  • Assets: 26.2B $
  • Debt: 3.4B $
  • Employees: 49,295 people
  • Free cash flow: 7.3B $
  • Market cap: 239.6B $
  • Profits: 6.4B $
  • Revenues: 20.1B $

Stocks from Novo Nordisk

Explore more on business

Talking Points:

  • Novo Nordisk | driving change to defeat serious chronic diseases
  • Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases.
  • Daily news about diabetes, obesity and other serious chronic diseases. We're global, but here in person for your questions and comments 💬 Community guide 👇
  • Driving change to defeat diabetes and other serious chronic diseases. Join us to learn more about our latest innovations | Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and ...
  • Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Learn more about talking points

In literature

There is no book written about Novo Nordisk in our database

Related

Connected or similar:

Details

This dashboard is based on data from: YAHOO-FIN, YFINANCE, Twitter

This content can be used under the CC BY 4.0 license